Lilly and Boehringer Halt $2bn German Investments as Pharma Industry Protests Drug Spending Curbs
核心洞察
Eli Lilly has halved its planned investment in a Rhineland-Palatinate biopharmaceutical facility, putting up to $1.5bn and a significant share of jobs in question.
Boehringer Ingelheim has paused approximately €900m in planned German investments, citing government interventions in statutory health insurance drug spending.
Pfizer CEO Albert Bourla has also signaled a reevaluation of German investments in a letter to Chancellor Friedrich Merz over proposed drug price caps.
Eli Lilly and Boehringer Ingelheim have independently paused major investment projects in Germany, collectively worth approximately $2 billion, citing the German government's planned interventions in statutory health insurance drug spending. The decisions mark a significant escalation in tensions between the pharmaceutical industry and European governments over drug pricing and cost-containment measures.
Lilly announced it would reduce the not-yet-implemented portion of its major project in Alzey, Rhineland-Palatinate, by around half. The production facility for biopharmaceutical medicines is still scheduled to begin operations in 2027, but with lower capacity than originally planned. According to the company, investments of up to $1.5bn, as well as a significant share of the jobs originally planned, are now in question. In 2023, Lilly had announced total investments of $2.5bn for the site. Construction is already well advanced, with interior work under way, and several hundred employees have been hired. The company stated that any decision on further expansion will now depend on future economic and regulatory conditions in Germany.
Boehringer Ingelheim has also halted its investment plans. The family-owned company had intended to invest approximately €900m in German sites over the next four years, including in new research and laboratory buildings. The company directly cites the government's planned interventions as the reason, with the industry particularly critical of additional rebate and savings measures, which it argues undermine the long-term predictability needed for investment.
Pfizer joins the chorus of concern
The development has been further amplified by Pfizer, whose CEO Albert Bourla communicated to Chancellor Friedrich Merz that the company is reevaluating its planned investments in Germany due to concerns over new government proposals to limit drug pricing. Bourla's letter highlighted uncertainties affecting the pharmaceutical industry's long-term strategic decisions. While Pfizer did not detail which investments might be affected, the sentiment echoes wider industry fears about the implications of proposed cost-containment measures in Germany's healthcare system.
A broader competitiveness crisis
The investment freezes come at a time of growing international competition for pharmaceutical and biotechnology investment. While the United States is attracting production and research capacity through industrial-policy incentives and extensive funding programmes, Asian countries are also investing heavily in their life sciences industries. Against this backdrop, companies have long warned of a gradual deterioration in Europe's attractiveness as a business location.
An analysis by European Biotechnology of the 38 novel active substances approved by the European Medicines Agency last year shows that only around 30% can be traced to a scientific origin in Europe. The majority originate in the United States, with a clear concentration in the Boston region. In Europe, the research sites behind these substances are located in Switzerland, the UK, and France; not a single active substance originated in Germany.
This dependence is also reflected in the fact that, among medicines recently approved by the FDA as novel active substances — those addressing medical conditions for which no treatment had previously been available — around 30% do not reach patients in Germany. Industry associations, including vfa and BPI, have repeatedly pointed this out in recent months, citing the healthcare policy framework as the reason.
Industry associations sound the alarm
Pharma Deutschland and vfa both view the decisions by Lilly and Boehringer as a dramatic turn of events. Jörg Wieczorek, chairman of Pharma Deutschland, stated: "The withdrawal by Lilly and Boehringer Ingelheim is a strong warning signal and a signpost for the economic policy of this federal government. Companies that wanted to invest billions in Germany without subsidies are reversing that decision. This means our fears have come true: a pharmaceutical dialogue in which, apparently, no one in the federal government apart from the health ministry has any interest, and a statutory health insurance savings law that destroys confidence in Germany as a location, cannot remain without consequences."
Wieczorek added: "If the federal government now claims to have been surprised by these decisions, it should be clear to the last remaining industry that this government lacks awareness of what is needed for economic recovery."
The state government of Rhineland-Palatinate has announced that it would seek talks with both companies at short notice. According to sources in Mainz, economic competitiveness and the stabilisation of statutory health insurance must both be taken into account. Whether the decisions by Lilly and Boehringer are isolated cases or the first signs of a broader reluctance to invest will now be watched closely by the industry.